Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97


Bi treatment with hydralazine/nitrates vs. placebo in Africans admitted with acute HEart Failure (BA-HEF).

Sliwa K, Damasceno A, Davison BA, Mayosi BM, Sani MU, Ogah O, Mondo C, Ojji D, Dzudie A, Kouam CK, Yonga G, Ba SA, Ogola E, Edwards C, Milo O, Cotter G.

Eur J Heart Fail. 2016 Oct;18(10):1248-1258. doi: 10.1002/ejhf.581. Epub 2016 May 20.


Effect of fixed-dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure: results from the African-American Heart Failure Trial.

Anand IS, Win S, Rector TS, Cohn JN, Taylor AL.

Circ Heart Fail. 2014 Sep;7(5):759-65. doi: 10.1161/CIRCHEARTFAILURE.114.001360. Epub 2014 Jun 26.


Fixed-dose isosorbide dinitrate-hydralazine: race-based cardiovascular medicine benefit or mirage?

Ferdinand KC.

J Law Med Ethics. 2008 Fall;36(3):458-63. doi: 10.1111/j.1748-720X.2008.291.x. Review.


Isosorbide Dinitrate, With or Without Hydralazine, Does Not Reduce Wave Reflections, Left Ventricular Hypertrophy, or Myocardial Fibrosis in Patients With Heart Failure With Preserved Ejection Fraction.

Zamani P, Akers S, Soto-Calderon H, Beraun M, Koppula MR, Varakantam S, Rawat D, Shiva-Kumar P, Haines PG, Chittams J, Townsend RR, Witschey WR, Segers P, Chirinos JA.

J Am Heart Assoc. 2017 Feb 20;6(2). pii: e004262. doi: 10.1161/JAHA.116.004262.


Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.

Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN; African-American Heart Failure Trial Investigators.

N Engl J Med. 2004 Nov 11;351(20):2049-57. Epub 2004 Nov 8. Erratum in: N Engl J Med. 2005 Mar 24;352(12):1276.


A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, et al.

N Engl J Med. 1991 Aug 1;325(5):303-10.


Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial.

Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, Taylor M, Adams K, Olukotun AY, Ofili E, Tam SW, Sabolinski ML, Worcel M, Cohn JN; African-American Heart Failure Trial Investigators.

Circulation. 2007 Apr 3;115(13):1747-53. Epub 2007 Mar 19.


Effects of nitrates and hydralazine in heart failure: clinical evidence before the african american heart failure trial.

Elkayam U, Bitar F.

Am J Cardiol. 2005 Oct 10;96(7B):37i-43i. Epub 2005 Aug 9. Review.


Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.

Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, et al.

N Engl J Med. 1986 Jun 12;314(24):1547-52.


Fixed-Dose Versus Off-Label Combination of Isosorbide Dinitrate Plus Hydralazine Hydrochloride: Retrospective Propensity-Matched Analysis in Black Medicare Patients with Heart Failure.

Ofili E, Anand I, Williams RA, Akinboboye O, Xu L, Puckrein G.

Adv Ther. 2017 Aug;34(8):1976-1988. doi: 10.1007/s12325-017-0584-x. Epub 2017 Jul 13.


African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology.

Franciosa JA, Taylor AL, Cohn JN, Yancy CW, Ziesche S, Olukotun A, Ofili E, Ferdinand K, Loscalzo J, Worcel M; A-HeFT Investigators.

J Card Fail. 2002 Jun;8(3):128-35.


Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial.

Anand IS, Tam SW, Rector TS, Taylor AL, Sabolinski ML, Archambault WT, Adams KF, Olukotun AY, Worcel M, Cohn JN.

J Am Coll Cardiol. 2007 Jan 2;49(1):32-9. Epub 2006 Dec 14.


Evidence for the continued safety and tolerability of fixed-dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African-American Heart Failure Trial).

Yancy CW, Ghali JK, Braman VM, Sabolinski ML, Worcel M, Archambault WT, Franciosa JA.

Am J Cardiol. 2007 Aug 15;100(4):684-9. Epub 2007 Jun 26.


Adjuvant therapy of chronic refractory cardiac failure with oral hydralazine and isosorbide dinitrate.

Kothiala A, Ramnani K, Patel HR, Mehta NC, Shah CP.

J Assoc Physicians India. 1983 Jun;31(6):343-6. No abstract available.


Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial.

Ferdinand KC, Elkayam U, Mancini D, Ofili E, PiƱa I, Anand I, Feldman AM, McNamara D, Leggett C.

Am J Cardiol. 2014 Jul 1;114(1):151-9. doi: 10.1016/j.amjcard.2014.04.018. Epub 2014 Apr 18. Review.


Usefulness of Isosorbide Dinitrate and Hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure.

Mullens W, Abrahams Z, Francis GS, Sokos G, Starling RC, Young JB, Taylor DO, Tang WH.

Am J Cardiol. 2009 Apr 15;103(8):1113-9. doi: 10.1016/j.amjcard.2008.12.028. Epub 2009 Feb 21.

Supplemental Content

Support Center